Serum testosterone levels and Colonic Diverticula

Background: Elderly men have a high risk of metabolic syndrome, including an increased risk of obesity. Whether low testosterone is associated with diverticular disease of the colon (DDC) risk independent of metabolic co-factors is not clear. Aim: This study was conducted this study to reveal the possible link between serum testosterone levels and colonic diverticula. Methods: This study was conducted between May 2018 and December 2018, total 208 subjects were enrolled for the study at a university hospital, Turkey. At total, 85 men with DDC were enrolled for the study. DDC was defined by non-contrast CT scan with colonoscopic examination. Control group (123 subjects without DDC; the mean age was 54.5 ±14.5) were selected from otherwise healthy men. Results: Of the 85 men with DDC, the mean age was 60.8 ± 13.5 years. Lower levels of total testosterone were associated with a 25% increased odds of prevalent DDC on adjusted analyses. Importantly, lower levels of total testosterone remained strongly associated with prevalent DDC, even in men with normal glucose levels (p=0.01). Conclusion: Decreasing levels of total testosterone, even within normal range, are independently associated with DDC in elderly age. Androgen deficiency may have an important role in the development of DDC in men and provide a potential novel target for DDC prevention

Chemical composition, antioxidant, antimicrobial and anticancer activities of endemic Cephalaria tuteliana

Introduction: The genus Cephalaria, belonging to the Caprifoliaceae family, is a rich source of secondary metabolites, including mainly saponins which display a variety of biological activities, such as antimicrobial, antioxidant, and anticancerous effects. This study was carried out to observe the biochemical composition and to evaluate the biological activities of Cephalaria tuteliana Kus & Gokturk. Methods: The composition of endemic C. tuteliana was determined through gas chromatography-mass spectrometry (GC–MS) studies. Antimicrobial effect were determined by the disk diffusion and dilution methods for test bacteria and test fungi. The antioxidant potential of the ethanol extract was also investigated. Cell proliferation and apoptosis analysis were investigated by WST-1 and ELISA methods. The migration level of PC-3 prostate cancer cells after plant extract application was examined by wound healing assay. Also, molecular docking experiments were performed to investigate the anticancer activity of the major component found in the C.tuteliana extract. Results: GC–MS analysis showed that the predominant compounds were Phenol, 2,2′-methylenebis [6-(1,1dimethyl ethyl)-4-methyl- (23.54 %), 9,12,15-octadecatrien-1-ol, (Z,Z,Z)-(6.06 %) and n-Hexadecanoic acid (3.03 %). The ethanolic extract of C. tuteliana displayed moderate antimicrobial activity against a spectrum of tested microorganisms. Also, it exhibited significant antiproliferative effects on PC-3 human prostate cancer cells while having no harmful effects on healthy control HUVEC cells. Furthermore, enhanced expressions of Caspase-3, 8, and 9 were observed in PC-3 cells after plant extract treatment. Also, cell migration level was notably reduced, especially at a dose of 400 µg/mL in PC-3 cells. The DPPH free radical scavenging activity of ethanolic extracts of C. tuteliana showed higher activity than ascorbic acid. Molecular docking experiments showed potential binding of the major aromatic compound in C.tuteliana extract to human androgen receptor 1E3G protein. Conclusion: These findings highlight the potential of C. tuteliana as a valuable natural resource and pave the way for further in vivo prostate cancer investigations

The effects of high-rate frequency modulation treatment on malondialdehyde in diabetic polineuropaty

WOS: 000239590003627

Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results

ALBUZ, OZGUR/0000-0002-8534-1781WOS: 000471268100006PubMed: 31320819Boron oxide (B2O3) is derived from dehydration of boric acid and is a colorless, semitransparent, crystalline compound that is moderately soluble in water. On the other hand, boron oxide is chemically hygroscopic. This gives the molecule the ability to soak up water and adhere to tissues. Boron oxide can be used locally after tumor debulking in inoperable tumors and especially when the twnor-free margin distance cannot be provided. For all these reasons we aimed to evaluate the in vitro test results of B2O3, in terms of cytotoxicity, genotoxicity, apoptosis, and necrotic effects on L929 fibroblast cells and DLD-1 colorectal adenocarcinoma cells. Our studies demonstrated that boron oxide compounds appear to be highly cytotoxic for both cell lines according to WST cell viability assay (44.22% and 18.36% on DLD-1 and L929, respectively). Although no genotoxic effects were observed, boron oxide compounds showed antiproliferative effects for both cell lines. The prepared boron oxide compounds may hold the potential to be applied locally to the remaining tissue after surgery and further research and evaluation will be needed to determine its effectivenesss

Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01

The MF07-01 trial is a multicenter, phase III, randomized, controlled study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone for treatment-na < ve stage IV breast cancer (BC) patients

Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01

The MF07-01 trial is a multicenter, phase III, randomized, controlled study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone for treatment-na < ve stage IV breast cancer (BC) patients. At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. The trial enrolled 274 patients: 138 in the LRT group and 136 in the ST group. Hazard of death was 34% lower in the LRT group than in the ST group (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.49-0.88; p = 0.005). Unplanned subgroup analyses showed that the risk of death was statistically lower in the LRT group than in the ST group with respect to estrogen receptor (ER)/progesterone receptor (PR)(+) (HR 0.64; 95% CI 0.46-0.91; p = 0.01), human epidermal growth factor 2 (HER2)/neu(-) (HR 0.64; 95% CI 0.45-0.91; p = 0.01), patients younger than 55 years (HR 0.57; 95% CI 0.38-0.86; p = 0.007), and patients with solitary bone-only metastases (HR 0.47; 95% CI 0.23-0.98; p = 0.04). In the current trial, improvement in 36-month survival was not observed with upfront surgery for stage IV breast cancer patients. However, a longer follow-up study (median, 40 months) showed statistically significant improvement in median survival. When locoregional treatment in de novo stage IV BC is discussed with the patient as an option, practitioners must consider age, performance status, comorbidities, tumor type, and metastatic disease burden